Porous β-tricalcium phosphate granules for regeneration of bone tissue
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-002/00
C12N-011/14
C07K-017/14
출원번호
US-0960789
(2001-09-21)
발명자
/ 주소
Dalal, Paresh S.
Dimaano, Godofredo R.
Toth, Carol Ann
Kulkarni, Shailesh C.
출원인 / 주소
Stryker Corporation
대리인 / 주소
Ropes &
인용정보
피인용 횟수 :
116인용 특허 :
111
초록▼
A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix
A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous β-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous β-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous β-TCP material and inducing bone formation are also provided.
대표청구항▼
1. A composition comprising porous β-tricalcium phosphate (β-TCP) granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 20-500 μm and being single separate voids partitioned by walls and being not interconnected.2. A composition compr
1. A composition comprising porous β-tricalcium phosphate (β-TCP) granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 20-500 μm and being single separate voids partitioned by walls and being not interconnected.2. A composition comprising porous β-TCP granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 410-460 μm and being single separate voids partitioned by walls and being not interconnected.3. A composition comprising porous β-TCP granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 40-190 μm and being single separate voids partitioned by walls and being not interconnected.4. A composition comprising porous β-TCP granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 20-95 μm and being single separate voids partitioned by walls and being not interconnected.5. A composition comprising porous β-TCP granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 50-125 μm and being single separate voids partitioned by walls and being not interconnected.6. The composition of any one of claims 1 to 5, wherein said β-TCP granules have a particle size of 0.5-1.7 mm.7. The composition of any one of claims 1 to 5, wherein said β-TCP granules have a particle size of 1-1.7 mm.8. The composition of any one of claims 1 to 5, wherein said β-TCP granules have a particle size of 0.5-1.0 mm.9. The composition of any one of claims 1 to 5, wherein the total porosity of said β-TCP granules is in the range of5-80%.10. The composition of any one of claims 1 to 5, wherein the total porosity of said β-TCP granules is in the range of 40-80%.11. The composition of any one of claims 1 to 5, wherein the total porosity of said β-TCP granules is in the range of 65-75%.12. The composition of any one of claims 1 to 5, wherein the total porosity of said β-TCP granules is 70%.13. The composition of any one of claims 1 to 5, further comprising a bioactive agent.14. The composition of claim 13, wherein the bioactive agent is a bone morphogenic protein.15. The composition of claim 14, wherein the bone morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, COP-1, COP-3, COP-4, COP-5, COP-7, COP-16, BMP-2, BMP-3, B-3b, BMP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, MP121, dorsalin-1, DPP, Vg-1, Vgr-1, 60A protein, NODAL, UNIVIN, SCREW, ADMP, NEURAL, TGF-β and conservative amino acid sequence variants thereof having osteogenic activity.16. The composition of claim 13, wherein the bioactive agent is an osteogenic protein comprising an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids of human OP-1.17. The composition of claim 14 further comprising a morphogenic protein stimulatory factor.18. The composition of claim 17, wherein the morphogenic protein stimulatory factor is selected from the group consisting of insulin-like growth factor I (IGF-I), estradiol, fibroblast growth factor (FGF), growth hormone (GH), growth and differentiation factor (GDF), hydrocortisone (HC), insulin, progesterone, parathyroid hormone (PTH), vitamin D, retinoic acid and IL-6.19. The composition of claim 13, wherein the bioactive agent is a nucleic acid molecule comprising a sequence encoding a bone morphogenic protein.20. The composition of claim 13, wherein the bioactive agent is encapsulated in a biodegradable agent.21. The composition of claim 20, wherein the biodegradable agent is selected from the group consisting of ethylenevinylacetate, natural and synthetic collagen, poly(glaxanone), poly(phosphazenes), polyglactin, polyglactic acid, polyaldonic acid, polyacrylic acids, polyalkanoates, polyorthoesters, poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), poly(ζ-caprolactone), poly(trimethylene carbonate), poly(p-doxanone), poly(ζ-caprolactone-co-glycolide), poly(glycolide-co-trimethylene carbonate) poly(D,L-lactide-co-trimethylene carbonate), polyarylates, polyhydroxybutyrate (PHB), polyanhydrides, poly(anhydride-co-imide) and co-polymers thereof, polymers of amino acids, propylene-co-fumarates, a polymer of one or more α-hydroxy carboxylic acid monomers, bioactive glass compositions, admixtures thereof and any derivatives and modifications thereof.22. The composition of claim 21, wherein the PLGA has a molecular weight of 5 kD to 500 kD.23. The composition of claim 21, wherein the PLGA has a molecular weight of 10 kD to 30 kD.24. The composition of claim 13, wherein the bioactive agent is an allograft or autograft.25. The composition of claim 5, wherein the porous β-TCP granules have a particle size of 0.5-1 mm.26. The composition of claim 25, wherein the composition further comprises carboxy methylcellulose sodium as a binder, and is moldable putty.27. A kit comprising the composition of claim 25, and carboxy methylcellulose sodium.28. A kit comprising: a) the composition of any one of claims 1 to 5; and b) a bioactive agent.29. The kit of claim 28, wherein the bioactive agent is a bone morphogenic protein.30. The kit of claim 29, wherein the bone morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, COP-1, COP-3, COP-4, COP-5, COP-7, COP-16, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, MP-17, BMP-18, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, G-10, GDF-11, GDF-12, MP121, dorsalin-1, DPP, Vg-1, Vgr-1, 60A protein, NODAL, UNIVIN, SCREW, ADMP, NEURAL, TGF-β and conservative amino acid sequence variants thereof having osteogenic activity.31. The kit of claim 28, wherein the bioactive agent is an osteogenic protein comprising an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids of human OP-1.32. The kit of claim 29 further comprising a morphogenic protein stimulatory factor.33. The kit of claim 32, wherein the morphogenic protein stimulatory factor is selected from the group consisting of insulin-like growth factor I (IGF-I), estradiol, fibroblast growth factor (FGF), growth hormone (GH), growth and differentiation factor (GDF), hydrocortisone (HC), insulin, progesterone, parathyroid hormone (PTH), vitamin D, retinoic acid and IL-6.34. A kit comprising: a) the composition of any one of claims 1 to 5; and b) a binder.35. The kit of claim 34, wherein the binder is selected from the group consisting of sodium alginate, hyaluronic acid, sodium hyaluronate, gelatin, collagen, peptides, mucin, chrondroitin sulfate, chitosan, poloxamer, glycosaminoglycan, polysaccharide, polyethylene glycol, methylcellulose, carboxy methylcellulose, carboxy methylcellulose sodium, carboxy methylcellulose calcium, hydroxypropyl methylcellulose, hydroxybutyl methylcellulose, hydroxyethyl methylcellulose, hydroxyethylcellulose, methylhydroxyethyl cellulose, hydroxyethyl cellulose, polylactic acid, polyglycolic acid, co-polymers of polylactic acid and polyglycolic acid, polyhydroxybutyric acid, polymalic acid, polyglutamic acid, polylactone, mannitol, white petrolatum, mannitol/dextran combinations, mannitol/white petrolatum combinations, sesame oil, fibrin glue and admixtures thereof.36. The kit of claim 35, wherein the fibrin glue is formed from human fibrinogen and thrombin.37. A moldable putty composition comprising the composition of any one of claims 1 to 5 and a binder.38. The moldable putty composition of claim 37, wherein the binder is selected from the group consisting of sodium alginate, hyaluronic acid, sodium hyaluronate, gelatin, collagen, peptides, mucin, chrondroitin sulfate, chitosan, poloxamer, glycosaminoglycan, polysaccharide, polyethylene glycol, methylcellulose, carboxy methylcellulose, carboxy methylcellulose sodium, carboxy methylcellulose calcium, hydroxypropyl methylcellulose, hydroxybutyl methylcellulose, hydroxyethyl methylcellulose, hydroxyethylcellulose, methylhydroxyethyl cellulose, hydroxyethyl cellulose, polylactic acid, polyglycolic acid, co-polymers of polylactic acid and polyglycolic acid, polyhydroxybutyric acid, polymalic acid, polyglutamic acid, polylactone, mannitol, white petrolatum, mannitol/dextran combinations, mannitol/white petrolatum combinations, sesame oil, fibrin glue and admixtures thereof.39. The moldable putty composition of claim 38, wherein the fibrin glue is formed from human fibrinogen and thrombin.40. The moldable putty composition of claim 37 further comprising a bioactive agent.41. An implantable prosthetic device comprising: a) a prosthetic implant having a surface region implantable adjacent to a target tissue; and b) the composition of any one of claims 1 to 5 disposed on the surface region.42. The prosthetic device of claim 41, wherein the composition further comprises a bioactive agent.43. The prosthetic device of claim 42, wherein the bioactive agent is a bone morphogenic protein.44. The prosthetic device of claim 43, wherein the bone morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, COP-1, COP-3, COP-4, COP-5, COP-7, COP-16, BMP-2, BMP-3, BMP-3b, MP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, B-15, BMP-16, BMP-17, BMP-18, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, MP121, dorsalin-1, DPP, Vg-1, Vgr-1, 6 A protein, NODAL, UNIVIN, SCREW, ADMP, NEURAL, TGF-β and conservative amino acid sequence variants thereof having osteogenic activity.45. The prosthetic device of claim 42, wherein the bioactive agent is an osteogenic protein comprising an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids of human OP-1.46. The prosthetic device of claim 43 further comprising a morphogenic protein stimulatory factor.47. The prosthetic device of claim 46, wherein the morphogenic protein stimulatory factor is selected from the group consisting of insulin-like growth factor I (IGF-I), estradiol, fibroblast growth factor (FGF), growth hormone (GH), growth and differentiation factor (GDF), hydrocortisone (HC), insulin, progesterone, parathyroid hormone (PTH), vitamin D, retinoic acid an IL-6.48. The prosthetic device of claim 42, wherein the bioactive agent is a nucleic acid molecule comprising a sequence encoding a bone morphogenic protein.49. The prosthetic device of claim 42, wherein the bioactive agent is encapsulated in a biodegradable agent.50. The prosthetic device of claim 49, wherein the biodegradable agent is selected from the group consisting of ethylenevinylacetate, natural and synthetic collagen, poly(glaxanone), poly(phosphazenes), polyglactin, polyglactic acid, polyaldonic acid, polyacrylic acids, polyalkanoates, polyorthoesters, poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), poly(ζ-caprolactone), poly(trimethylene carbonate), poly(p-dioxanone), poly(ζ-caprolactone-co-glycolide), poly(glycolide-co-trimethylene carbonate), poly(D,L-lactide-co-trimethylene carbonate), polyarylates, polyhydroxybutyrate (PHB), polyanhydrides, poly(anhydride-co-imide) and co-polymers thereof; polymers of amino acids, propylene-co-fumarates, a polymer of one or more α-hydroxy carboxylic acid monomers, bioactive glass compositions, admixtures thereof and any derivatives and modifications thereof.51. The prosthetic device of claim 50, wherein the PLGA has a molecular weight of 5 kD to 500 kD.52. The prosthetic device of claim 50, wherein the PLGA has a molecular weight of 10 kD to 30 kD.53. The prosthetic device of claim 41, wherein the device is selected from the group consisting of a hip device, a fusion cage and a maxillofacial device.54. The prosthetic device of claim 41, wherein the composition further comprises a binder.55. The prosthetic device of claim 54, wherein the binder is selected from the group consisting of sodium alginate, hyaluronic acid sodium hyaluronate, gelatin, collagen, peptides, mucin, chrondroitin sulfate, chitosan, poloxamer, glycosaminoglycan, polysaccharide, polyethylene glycol, methylcellulose, carboxy methylcellulose, carboxy methylcellulose sodium, carboxy methylcellulose calcium, hydroxypropyl methylcellulose, hydroxybutyl methylcellulose, hydroxyethyl methylcellulose, hydroxyethylcellulose, methylhydroxyethyl cellulose, hydroxyethyl cellulose, polylactic acid, polyglycolic acid, co-polymers of polylactic acid and polyglycolic acid, polyhydroxybutyric acid, polymalic acid, polyglutamic acid, polylactone, mannitol, white petrolatum, mannitol/dextran combinations, mannitol/white petrolatum combinations, sesame oil, fibrin glue and admixtures thereof.56. The prosthetic device of claim 55, wherein the fibrin glue is formed from human fibrinogen and thrombin.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (111)
Richter Paul Wilhelm,ZAX ; Thomas Michael Edward,ZAX, Artefact suitable for use as a bone implant.
Starling L. Brian (Golden CO) Stephan James E. (Arvada CO) Hubbard William G. (Lakewood CO), Biocompatible particles and cloth-like article made therefrom.
Takagi Shigehide (Tokyo JPX) Ito Kuniomi (Tochigi-ken JPX) Hidaka Tsuneo (Tokyo JPX), Ceramic device providing an environment for the promotion and formation of new bone.
Dorman Linneaus C. (Midland MI) Meyers Paul A. (Dublin CA), Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics.
Graves ; Jr. George A. (Bellbrook OH) McCullum Dale E. (Vandalia OH) Goodrich Steven M. (Dayton OH), Controlled pore size ceramics particularly for orthopaedic and dental applications.
Lincoln Steve E. ; Klingler Tod M. ; Au-Young Janice ; Tang Y. Tom ; Goold Richard D. ; Akerblom Ingrid E. ; Seilhamer Jeffrey J. ; Hawkins Phillip R. ; Murry Lynn E. ; Delegeane Angelo M. ; Levine W, Database for storage and analysis of full-length sequences.
Robey Pamela Gehron ; Bianco Paolo,ITX ; Kuznetsov Sergei ; Rowe David ; Krebsbach Paul ; Mankani Mahesh H., Formation of human bone in vivo using ceramic powder and human marrow stromal fibroblasts.
Tjia Jane S. (Malden MA) Kelley Brian D. (Medford MA) Northey Richard P. (Ipswich MA) Philbrook C. Michael (Boston MA), Formulations for delivery of osteogenic proteins.
Yim Kalvin W. K. (N. andover MA) Huberty Michael C. (Andover MA) Northey ; Jr. Richard P. (Ipswich MA) Schrier Jay A. (Andover MA), Formulations for delivery of osteogenic proteins.
Yasuharu Hakamatsuka JP; Hiroyuki Irie JP; Gen Horie JP, Hollow porous ceramic carrier for embedding in patient for sustained medicament release and method of preparation thereof.
Eitenmuller Jrgen (Brauweiler DEX) Rackur Helmut (Remchingen/Singen DEX) Wimmer Walter (Limburg/Lahn DEX) Weiss Marija (Limburg/Lahn DEX), Implant for filling bone cavities and fixing bone fragments in a living body, method of producing the same, and bone imp.
Draenert Klaus (Gabriel-Max-Str. 3 W-8000 Munchen 90 DEX), Material as a starting material for the preparation of bone cement, process for its preparation and process for the prep.
Lerch Alain,FRX ; Frayssinet Patrick,FRX, Method for preparing an implantable composite material, resulting material, implant including said material, and kit therefor.
Pathak Chandrashekhar P. ; Barman Shikha P. ; Philbrook C. Michael ; Sawhney Amarpreet S. ; Coury Arthur J. ; Avila Luis Z. ; Kieras Mark T., Multiblock biodegradable hydrogels for drug delivery and tissue treatment.
Ron Eyal (Lexington MA) Turek Thomas J. (Boston MA) Isaacs Benjamin S. (Tewksbury MA) Patel Himakshi (Tewksbury MA) Kenley Richard A. (Andover MA), Pharmaceutical formulations of osteogenic proteins.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H., Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Sonuparlak Birol (Seattle WA) Aksay Ilhan A. (Seattle WA), Process for the production of porous ceramics using decomposable polymeric microspheres and the resultant product.
Takai Nobuharu (Tokyo JPX) Noma Hiroyasu (Tokyo JPX) Wakabayashi Shoichi (Tokyo JPX) Takata Susumu (Tokyo JPX), Prosthetic body for bone substitute and a method for the preparation thereof.
Tsuru Sumiaki (Tokyo JPX) Tsugita Masashi (Tokorozawa JPX) Takasaki Ken (Tokyo JPX) Yokoo Akihiko (Tokyo JPX) Ichitsuka Takeshi (Tokyo JPX), Slow release drug delivery granules and process for production thereof.
Ammann Arthur J. (460 Point San Bruno Blvd. South San Francisco CA 94080-4990) Beck Steven L. (460 Point San Bruno Blvd. South San Francisco CA 94080-4990) Nguyen Tue H. (460 Point San Bruno Blvd. So, TGF-b
상세보기
Dingeldein Elvira (Dreieich DEX) Wahlig Helmut (Darmstadt DEX) Wotschokowsky Manfred (Darmstadt DEX) Moddelmog G (Darmstadt DEX), Tricalcium phosphate for implant materials wherein the pores of the tricalciumphosphate are filled with antibiotic and a.
Bhat, Archana; Kunjachan, Vipin; Geisler, Chris; Adams, Allison; Grimes, Christine, Biomaterial compositions, implants, and methods of making the same.
Asius, Jerome; Asius, Benedicte, Ceramic-based injectable implants which are used to fill wrinkles, cutaneous depressions and scars, and preparation method thereof.
Fritz, Ulf; Fritz, Olaf; Gordy, Thomas A.; Wojcik, Ronald; Blümmel, Jacques; Küller, Alexander, Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same.
Moseley, Jon P.; Carroll, Michael E.; McCanless, Jonathan D.; Schulz, Olaf; Fronk, Andy, Composite bone graft substitute cement and articles produced therefrom.
Moseley, Jon P.; Carroll, Michael E.; McCanless, Jonathan D.; Schulz, Olaf; Fronk, Andy, Composite bone graft substitute cement and articles produced therefrom.
Zamora, Paul O.; Atkinson, Brent Lee; Lin, Xinhua; Pena, Louis A., Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis.
Zamora, Paul O.; Atkinson, Brent Lee; Lin, Xinhua; Pena, Louis A., Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis.
Zamora, Paul; Atkinson, Brent Lee; Lin, Xinhua; Pena, Louis A., Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis.
Zamora, Paul; Atkinson, Brent Lee; Lin, Xinhua; Pena, Louis A., Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis.
Myung, David; Jaasma, Michael J.; Kourtis, Lampros; Chang, Daniel; Frank, Curtis W., Hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same.
Fritz, Ulf; Fritz, Olaf; Gordy, Thomas A.; Wojcik, Ronald; Blümmel, Jacques; Küller, Alexander, Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same.
Fritz, Ulf; Fritz, Olaf; Gordy, Thomas A.; Wojcik, Ronald; Blümmel, Jacques; Küller, Alexander, Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same.
Harder, Philipp; Fritz, Olaf; Fritz, Ulf, Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same.
Harder, Philipp; Fritz, Olaf; Fritz, Ulf, Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same.
Ying, Jackie Y.; Ahn, Edward S.; Nakahira, Atsushi, Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production.
Ying, Jackie Y.; Ahn, Edward S.; Nakahira, Atsuski, Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production.
Ying, Jackie Y.; Ahn, Edward S.; Nakahira, Atsuski, Nanocrystalline apatites and composites, prostheses incorporating them, and methods of their production.
Garigapati, Venkat R.; Hess, Brian J.; Kimsey, Cassandra L.; Murphy, Matthew E., Organophosphorous, multivalent metal compounds, and polymer adhesive interpenetrating network compositions and methods.
Rueger, David C.; Tucker, Marjorie M., Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects.
Rueger, David C.; Tucker, Marjorie M.; Chang, An-Cheng, Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects.
Rueger, David C.; Tucker, Marjorie M.; Chang, An-Cheng, Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects.
Lynch, Samuel E.; Wisner-Lynch, Leslie A.; Kestler, Hans K.; Liu, Yanchun, Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries.
Bagga, Charanpreet S.; Clineff, Theodore D.; Erbe, Erik M.; Paris, Michael W.; Nagvajara, Gina M.; Koblish, Antony, Shapeable bone graft substitute and instruments for delivery thereof.
Bagga, Charanpreet S.; Clineff, Theodore D.; Erbe, Erik M.; Paris, Michael W.; Nagvajara, Gina M.; Koblish, Antony, Shapeable bone graft substitute and instruments for delivery thereof.
Grunze, Michael; Fritz, Ulf, Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface.
McBride, Dennis; Clark, Joshua P.; Davis, Richard; Pomrink, Gregory J.; Tosun, Zehra; Greenspan, David C., System and kit for delivering collagen bioglass composite bone grafting materials for regenerating hard tissues.
Vanderploeg, Eric; Seeherman, Howard; Wilson, Christopher G.; Wozney, John; Brown, Christopher T.; Kambouris, John A., Systems and methods for improved delivery of osteoinductive molecules in bone repair.
Kourtis, Lampros; Jaasma, Michael J.; Myung, David; Hollis, Michael C.; Hartdegen, Vernon, Systems, devices, and methods for anchoring orthopaedic implants to bone.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.